文献速递胸部肿瘤

早期非小细胞肺癌立体定向体部放疗后远处转移预测:多机构模型的开发与外部验证

Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model.
PubMed 文献 · J Thorac Oncol · 2022-11-15

研究基于1280例cT1-3N0M0非小细胞肺癌患者的多机构数据库开发Fine and Gray模型预测1年远处转移风险,并在130例外部队列中验证,模型区分度AUC为0.70且校准良好,可识别高风险亚组。

要点

  • Fine and Gray模型预测1年远处转移风险,内部测试集AUC为0.71,外部验证集AUC为0.70。
  • 模型识别的高风险亚组1年远处转移率在内部测试集为20.0%对2.9%(p=0.001),外部验证集为21.4%对7.8%(p=0.095)。
  • 作者认为该模型可能有助于选择接受全身治疗的患者。

核心结论

  • 开发并外部验证了一个实用的模型,可预测接受立体定向体部放疗的非小细胞肺癌患者的远处转移风险,可能有助于选择全身治疗患者。

研究设计与样本

  • 多机构数据库纳入2006年至2015年接受立体定向体部放疗的1280例cT1-3N0M0非小细胞肺癌患者,用于模型开发与内部验证。
  • 采用Fine and Gray回归模型预测1年远处转移风险,并与随机生存森林模型比较。
  • 表现更优的模型在来自另一机构的130例患者外部队列中评估。
  • 区分度采用时间依赖曲线下面积(AUC)评估,校准通过图形和Brier评分评估。

主要发现

  • 内部测试集中Fine and Gray模型AUC为0.71(95%CI:0.57-0.86),随机生存森林模型AUC为0.69(95%CI:0.63-0.85),Fine and Gray模型被选为进一步测试。
  • 外部验证中Fine and Gray模型AUC为0.70(95%CI:0.57-0.83),校准良好(Brier评分:0.08)。
  • 内部测试集中高风险亚组1年远处转移率为20.0%(3/15)对2.9%(7/241),p=0.001。
  • 外部验证集中高风险亚组1年远处转移率为21.4%(3/15)对7.8%(9/116),p=0.095。
  • 提供了模型列线图和在线应用。

关键数值与推荐

  • Fine and Gray模型内部测试集AUC 0.71(95%CI:0.57-0.86),随机生存森林模型AUC 0.69(95%CI:0.63-0.85)。
  • Fine and Gray模型外部验证AUC 0.70(95%CI:0.57-0.83),Brier评分0.08。
  • 内部测试集高风险亚组1年远处转移率20.0%(3/15)对2.9%(7/241),p=0.001。
  • 外部验证集高风险亚组1年远处转移率21.4%(3/15)对7.8%(9/116),p=0.095。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Distant metastases (DMs) are the primary driver of mortality for patients with early stage NSCLC receiving stereotactic body radiation therapy (SBRT), yet patient-level risk is difficult to predict. We developed and validated a model to predict individualized risk of DM in this population. METHODS: We used a multi-institutional database of 1280 patients with cT1-3N0M0 NSCLC treated with SBRT from 2006 to 2015 for model development and internal validation. A Fine and Gray (FG) regression model was built to predict 1-year DM risk and compared with a random survival forests model. The higher performing model was evaluated on an external data set of 130 patients from a separate institution. Discriminatory performance was evaluated using the time-dependent area under the curve (AUC). Calibration was assessed graphically and with Brier scores. RESULTS: The FG model yielded an AUC of 0.71 (95% confidence interval [CI]: 0.57-0.86) compared with the AUC of random survival forest at 0.69 (95% CI: 0.63-0.85) in the internal test set and was selected for further testing. On external validation, the FG model yielded an AUC of 0.70 (95% CI: 0.57-0.83) with good calibration (Brier score: 0.08). The model identified a high-risk patient subgroup with greater 1-year DM rates in the internal test (20.0% [3 of 15] versus 2.9% [7 of 241], p = 0.001) and external validation (21.4% [3 of 15] versus 7.8% [9 of 116], p = 0.095). A model nomogram and online application was made available. CONCLUSIONS: We developed and externally validated a practical model that predicts DM risk in patients with NSCLC receiving SBRT which may help select patients for systemic therapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gao SJ, Jin L, Meadows HW, et al. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. J Thorac Oncol. 2022. PMID: 36396062. doi:10.1016/j.jtho.2022.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。